Table 1
Demographics, previous treatments, CNV characteristics, and visual acuity at presentation and at last follow up in six patients with subfoveal CNV secondary to PIC and POHS treated with PDT
| Patient number | Age | Sex | Eye | Diagnosis | Previous immunosuppression | CNV location | Size CNV GLD (mm) | Size CNV area (mm2) | Baseline VA* | VA* at last follow up | Number of PDT treatments | Follow up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VA*, visual acuity: Snellen equivalent (ETDRS VA score); CNV, choroidal neovascular membrane; GLD, greatest linear diameter; ETDRS, Early Treatment Diabetic Retinopathy Study; PDT, photodynamic therapy; POHS, presumed ocular histoplasmosis syndrome; PIC, punctate inner choroidopathy. | ||||||||||||
| 1 | 38 | M | R | PIC | Prednisolone; cyclosporin A | Subfoveal | 1.54 | 1.20 | 20/500 (5) | 20/250 (18) | 2 | 10 |
| 2 | 36 | F | R | PIC | Prednisolone; tacrolimus | Subfoveal | 1.22 | 0.72 | 20/160 (28) | 20/40 (52) | 3 | 12 |
| 3 | 41 | F | R | POHS | Prednisolone; cyclosporin A | Juxtafoveal | 2.15 | 2.99 | 20/126 (32) | 20/40 (55) | 2 | 9 |
| 4 | 35 | F | R | POHS | Prednisolone; cyclosporin A | Subfoveal | 4.08 | 9.35 | 20/250 (13) | 20/160 (21) | 2 | 20 |
| 5 | 37 | F | L | PIC | Prednisolone | Subfoveal | 1.16 | 0.73 | 20/160 (24) | 20/32 (66) | 2 | 10 |
| 6 | 58 | F | R | PIC | Prednisolone | Subfoveal | 1.64 | 1.48 | 20/32 (61) | 20/26 (64) | 4 | 11 |
